WASHINGTON, Nov. 11, 2024 (GLOBE NEWSWIRE) -- As policymakers increasingly move to impose government price setting on innovative medicines, it is essential to anchor these decisions to a better ...
(MENAFN- GlobeNewsWire - Nasdaq) Access to Life-Saving Drugs can be Delayed or Denied when Regulators and Health Plans Rely on Outdated Cost-Effectiveness Analysis (CEA) Methodology WASHINGTON, Nov.
Certains résultats ont été masqués, car ils peuvent vous être inaccessibles.
Afficher les résultats inaccessibles
Commentaires